TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells

Qi-feng Cao1, Su-bo Qian, Ning Wang

  • 1Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China .

Abstract

Insights

Histone deacetylase inhibitors (HDACi) induce apoptosis in bladder cancer by upregulating the TRPM2 channel. This upregulation, driven by increased H3K9Ac in the TRPM2 promoter, is crucial for HDACi-mediated cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Histone deacetylase (HDAC) inhibition triggers cancer cell growth arrest and apoptosis.
  • While p21 mediates HDAC inhibitor (HDACi)-induced growth inhibition, the mechanisms of HDACi-induced apoptosis in bladder cancer are not fully understood.

Purpose of the Study:

  • To investigate the mechanism of HDAC inhibitor-induced apoptosis in bladder cancer cells.
  • To determine the role of Transient Receptor Potential Cation Channel, Subfamily M, Member 2 (TRPM2) in this process.

Main Methods:

  • T24 bladder cancer cells were treated with HDACi (trichostatin A, sodium butyrate).
  • Apoptosis was assessed via flow cytometry; TRPM2 expression was analyzed using real-time PCR.
  • TRPM2 knockdown/overexpression and chromatin-immunoprecipitation were employed to elucidate TRPM2's role and the underlying regulatory mechanism.

Main Results:

  • HDACi treatment led to time- and dose-dependent apoptosis and TRPM2 upregulation in T24 cells.
  • TRPM2 overexpression enhanced apoptosis, while TRPM2 depletion inhibited HDACi-induced apoptosis.
  • HDAC inhibition increased H3K9 acetylation (H3K9Ac) at the TRPM2 promoter, driving its upregulation.

Conclusions:

  • TRPM2 upregulation is essential for HDAC inhibitor-induced apoptosis in bladder cancer.
  • HDAC inhibition promotes apoptosis by increasing permissive chromatin marks (H3K9Ac) at the TRPM2 promoter.